Of note, besides postmenopausal women, breast cancer patients undergoing hormone therapy such as aromatase inhibitors as well as localized or metastatic prostate cancer patients treated with androgen deprivation therapy and/or new androgen receptor pathway inhibitors, are also affected [29,85]. Here, CYP19A1 is linked to breast carcinoma.